Zobrazeno 1 - 10
of 45
pro vyhledávání: '"P. Nos Mateu"'
Autor:
M I Iborra Colomino, A Garrido Marín, B Caballol Oliva, J M Huguet Malavés, L Arias García, F Mesonero Gismero, S J Fernández Prada, M M Boscá Watts, Á Ponferrada Díaz, X Calvet Calvo, A Gutiérrez Casbas, I Ordás Jiménez, L Ruiz Sanchez, B Sicilia Aladren, I Garcia de la Filia, E Domènech Morral, P Nos Mateu
Publikováno v:
Journal of Crohn's and Colitis. 17:i517-i518
Background Recently, a subcutaneous formulation of biosimilar infliximab (CT-P13) (SC-IFX) has been approved for inflammatory bowel disease (IBD). The aims of this study were to evaluate efficacy, safety, pharmacokinetics and patient experience follo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c71a5fbe50c93ef27fa5894654b922c0
https://doi.org/10.1093/ecco-jcc/jjac190.0513
https://doi.org/10.1093/ecco-jcc/jjac190.0513
Autor:
G D'Haens, C Taxonera, A Lopez-Sanroman, P Nos Mateu, S Danese, A Armuzzi, X Roblin, L Peyrin-Biroulet, R West, B Witteman, M Duijvestein, K Gecse, M Hulshoff, N Mostafavi, E Clasquin, Y Bouhnik, D Laharie
Publikováno v:
Journal of Crohn's and Colitis. 17:i19-i19
Background Crohn’s disease (CD) is a chronic, immune-mediated inflammatory condition of the intestine, for which the majority of patients still needs to undergo surgical resection. Following the most common intervention ileocolonic resection, the v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::684f21a543a83340873377a3055037e8
https://doi.org/10.1093/ecco-jcc/jjac190.0014
https://doi.org/10.1093/ecco-jcc/jjac190.0014
Autor:
Marqués-Miñana, R Iglesias-Gomez, T Palanques-Pastor, P Nos-Mateu, I Beltrán-García, A Ferrada-Gascó, M Centelles-Oria, O Ballesta-López, José Luis Poveda-Andrés
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Vedolizumab (VDZ) is an alternative in patients with inflammatory bowel disease (IBD) who have an inadequate response or loss of response to previous treatment with tumour necrosis factor-alpha (TNFα) antagonists. Therapeut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd3a28c299ef5b2e4224a9d3abddf1c6
https://doi.org/10.1136/ejhpharm-2020-eahpconf.211
https://doi.org/10.1136/ejhpharm-2020-eahpconf.211
Autor:
M Enriquez Rodriguez, Ollero Pena, A. Echarri Piudo, B Botella Mateu, D Martín Rodriguez, R Fraga Iriso, N. Manceñido Marcos, M I Calvo Moya, J L Pérez Calle, P Nos Mateu, G Molina Arriero, B Castro Senosiain, M. Pérez, M Sierra Ausín
Publikováno v:
Journal of Crohn's and Colitis. 14:S213-S214
Background One of the aims of the Spanish Working Group on inflammatory bowel disease IBD (GETECCU), is to improve the quality of life of their patients. Quality standards for IBD Units include educational and care support of IBD patients. A trained
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0335f9ee1e207d8103e0d3cb5c299c68
https://doi.org/10.1093/ecco-jcc/jjz203.281
https://doi.org/10.1093/ecco-jcc/jjz203.281
Publikováno v:
Journal of Crohn's and Colitis. 14:S237-S238
Background Ulcerative colitis (UC) and Crohn’s disease (CD) are inflammatory bowel diseases (IBD), characterised by chronic inflammation of the digestive tract. IBD patients have an increased risk of developing colorectal cancer (CRC) compared with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53384d37b493c627543aff0cd8e8c063
https://doi.org/10.1093/ecco-jcc/jjz203.327
https://doi.org/10.1093/ecco-jcc/jjz203.327
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
L Tortosa Seguí, J L Poveda, Renato Francisco Rodrigues Marques, A Garrido Marín, D Muñoz Gómez, G Bastida Paz, E Valero Pérez, J Del Hoyo Francisco, S Bejar, P Nos Mateu, Mariam Aguas
Publikováno v:
Journal of Crohn's and Colitis. 14:S333-S333
Background Therapeutic drug monitoring (TDM) is used in inflammatory bowel disease to guide dosing of biologics to individualise drug exposure and optimise outcomes. In case of undetectable levels of Adalimumab (levels Methods Since October 13 to Aug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a07be15cd1b441e1b752834b9b627430
https://doi.org/10.1093/ecco-jcc/jjz203.476
https://doi.org/10.1093/ecco-jcc/jjz203.476
Autor:
R Palasí Giménez, Eduardo García-Granero, Matteo Frasson, Salvador Pous-Serrano, G Sanchez-Jordá, Jose Pamies-Guilabert, P Nos Mateu, M Llavador Ros
Publikováno v:
COLORECTAL DISEASE
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Aim to assess the accuracy of magnetic resonance-enterography in predicting the extension, location and characteristics of the small bowel segments affected by Crohn's disease. Method This is a prospective study including a consecutive series of 38 p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5ae99b6c0aa43a0c1572127ad028b0f
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=6913
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=6913
Autor:
J. A. Todolí Parra, R. Garcia Marcos, J.L. Moll Guillen, P. Nos Mateu, L.J. Martin Abad, Y. Tung Chen, M. Iborra Colomino
Publikováno v:
Revista Clínica Española. 214:e37-e40
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb4172ca502eb563301040eef7073735
https://doi.org/10.1016/j.rce.2014.01.012
https://doi.org/10.1016/j.rce.2014.01.012